OAM
VIRX

Oxford Asset Management’s Viracta Therapeutics, Inc. Common Stock VIRX Stock Holding History

Oxford Asset Management’s Portfolio VIRX Stock Details VIRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q3 		– Sell
-450
Closed -$33K – 1977
2018
Q2 		$33K Buy
+450
New +$40.1K ﹤0.01% 1663

Other funds holding VIRX

EAM
Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $77.1B AUM 42.89% 1-Year Est. Return
BC
Boxer Capital San Diego, California $2.04B AUM 108.39% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
NMC
NEA Management Company Timonium, Maryland $1.76B AUM 223.33% 1-Year Est. Return
PAI
Palo Alto Investors Palo Alto, California $654M AUM 77.8% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
RPAM
Rhenman & Partners Asset Management Stockholm, Sweden $810M AUM 30.2% 1-Year Est. Return

Oxford Asset Management's VIRX Position: Q3 2018 in Review

Oxford Asset Management sold out of Viracta Therapeutics, Inc. Common Stock (VIRX) in Q3 2018, closing a stake of 450 shares — an estimated $33K sold.

Oxford Asset Management first reported a position in VIRX in Q2 2018 and held it in 1 quarter. The position peaked at $33K in Q2 2018. 48 funds tracked by Wall St. Rank hold VIRX as of Q3 2018.

  • Oxford Asset Management reported no remaining Viracta Therapeutics, Inc. Common Stock position as of Q3 2018 after selling out during the quarter.
  • Oxford Asset Management sold 450 Viracta Therapeutics, Inc. Common Stock shares in Q3 2018, an estimated $33K.
  • Oxford Asset Management first reported a position in Viracta Therapeutics, Inc. Common Stock in Q2 2018 and held it in 1 quarter.
  • Oxford Asset Management's Viracta Therapeutics, Inc. Common Stock position peaked at $33K in Q2 2018.
  • 48 funds tracked by Wall St. Rank held Viracta Therapeutics, Inc. Common Stock as of Q3 2018.

Based on Oxford Asset Management's 13F filing for Q3 2018, filed 14 Nov 2018.